Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study

BACKGROUND: Immune checkpoint inhibitors (ICI) are dramatically active in a minority of non-small cell lung cancer (NSCLC) patients. We studied here the relationship between patients's metabolism and outcome under ICI. METHODS: Metastatic NSCLC patients underwent a nutritional assessment prior...

Descripción completa

Detalles Bibliográficos
Autores principales: Boudou-Rouquette, Pascaline, Arrondeau, Jennifer, Gervais, Claire, Durand, Jean-Philippe, Fabre, Elizabeth, De Percin, Sixtine, Villeminey, Clémentine Vaquin, Piketty, Anne-Catherine, Rassy, Nathalie, Ulmann, Guillaume, Damotte, Diane, Mansuet-Lupo, Audrey, Giraud, Frédérique, Alifano, Marco, Wislez, Marie, Alexandre, Jérôme, Jouinot, Anne, Goldwasser, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8536532/
https://www.ncbi.nlm.nih.gov/pubmed/34688030
http://dx.doi.org/10.1016/j.ebiom.2021.103630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8536532/
https://www.ncbi.nlm.nih.gov/pubmed/34688030
http://dx.doi.org/10.1016/j.ebiom.2021.103630

Ejemplares similares